报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2025-03-31 | 60.73% | 13.14% | 3.71% | 47/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
2024-12-31 | 58.56% | 4.73% | 0.58% | 51/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
2024-09-30 | 58.22% | 4.64% | 2.11% | 56/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 57.02% | 14.51% | 6.22% | 62/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 53.68% | 17.82% | -4% | 66/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 55.92% | 8.32% | 0.5% | 66/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 55.64% | 11.79% | 11.74% | 68/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 49.79% | -3.25% | 9.29% | 80/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 45.56% | -18.14% | -11.74% | 90/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 51.62% | 5.07% | 3.73% | 83/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 49.77% | 1.38% | -3.29% | 80/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 51.46% | 11.53% | -7.53% | 79/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 55.66% | 30.1% | 13.28% | 67/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 49.13% | 3.98% | 0.08% | 86/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 49.09% | -3.13% | 6.39% | 77/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 46.14% | -7.69% | 7.86% | 83/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
2021-03-31 | 42.78% | 2% | -9.46% | 79/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
2020-12-31 | 47.25% | -7.88% | -6.76% | 86/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
2020-09-30 | 50.68% | 2% | 1.39% | 67/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
2020-06-30 | 49.99% | 3.76% | -2.55% | 72/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
2019-12-31 | 51.3% | 9% | 6.48% | 74/158 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |
2019-06-30 | 48.18% | 2% | 2.38% | 66/158 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
2018-12-31 | 47.06% | -3.01% | -3.01% | 77/158 | -208.09% | 微芯生物 | 96.09% | 行业排名> |
2017-12-31 | 48.52% | 2% | 2% | 67/158 | 52.32% | 微芯生物 | 96.11% | 行业排名> |